Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | CCR3 | P51677 | 11/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3896148 | 1.00 | HTR3A (0.52) | HTR3ALMNAMAPTTP53NPSR1 | |
| SCHEMBL3885898 | 0.87 | CCR3 (0.68) | CCR3 | |
| SCHEMBL3896691 | 0.87 | CCR3 (0.68) | CCR3 | |
| SCHEMBL7779073 | 0.86 | KDM1A (0.48) | LMNAMAPTNPSR1CCR3MAPK1 | |
| SCHEMBL8989753 | 0.83 | CCR3 (0.50) | CCR3SMN1; SMN2 | |
| SCHEMBL7781809 | 0.81 | TMEM97 (0.51) | CCR3 | |
| SCHEMBL7781120 | 0.81 | CCR3 (0.53) | CCR3SMN1; SMN2 | |
| SCHEMBL7781108 | 0.79 | PLD1 (0.53) | CCR3 | |
| Cyclopropane SCHEMBL7076457 | 0.78 | PLD1 (0.41) | KMT2A | |
| Cyclopentane SCHEMBL7071125 | 0.78 | PLD1 (0.41) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040209876-A1 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | DUNCIA JOHN V (US) | 2004-10-21 | — | — | US | claimed |
| US-20040006084-A1 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | DUNCIA JOHN V (US) | 2004-01-08 | — | — | US | claimed |
| US-7550500-B2 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-20060014964-A1 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | DUNCIA JOHN V | 2006-01-19 | — | — | US | disclosed |
| US-6960666-B2 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20040209876-A1 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | DUNCIA JOHN V (US) | 2004-10-21 | — | — | US | disclosed |
| US-6784200-B2 | SUCH AS N-3-(CIS-2,3,3A,4,9,9A-HEXAHYDRO-1H-BENZ(F)ISOINDOL-2-YL)-N-PROP-1-YL-N'-3 -ACETYLPHENYLUREA FOR PREVENTION OF INFLAMMATORY DISEASES (ASTHMA AND ALLERGIES) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-31 | — | — | US | disclosed |
| US-20040006084-A1 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | DUNCIA JOHN V (US) | 2004-01-08 | — | — | US | disclosed |
| US-6586446-B1 | Chemotaxic cytokine agonists or antagonists such as N(3-acetylphlenyl)-N'-(-2-((-3-((4-fluorophenyl)methyl)-8 -azabicyclo(3.2.1)oct-8-yl)methyl)-(2R)-1-cyclohexyl)urea, used as antiinflammatory agents for asthma or allergies | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209876-A1 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | CCR1, CCR3, CCR10 | HTR3A 162/4885LMNA 3177/4885MAPT 4071/4885 |
| US-20040006084-A1 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | CCR1, CCR3, CCR10 | HTR3A 162/4885LMNA 3177/4885MAPT 4071/4885 |
| US-20060014964-A1 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | CCR3, CCR1, NR1I3 | HTR3A 129/4885LMNA 3395/4885MAPT 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.